| Abstract: | A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed. |
|
Patent landscape, scope, and claims: |
Summary
United States Patent 9,255,068 (U.S. Patent No. 9,255,068), granted to Novo Nordisk A/S on February 2, 2016, pertains to a novel pharmaceutical composition facilitating improved treatment options, likely within the realm of peptide-based therapeutics. This analysis dissects the patent’s scope, claims, inventive landscape, and implications for the broader drug patent framework. It offers a detailed exploration suited for stakeholders, including biotech companies, legal professionals, and R&D strategists, emphasizing patent boundaries, prior art considerations, and the competitive landscape.
What is the Scope of U.S. Patent 9,255,068?
Core Subject Matter
U.S. Patent 9,255,068 primarily covers a specific class of peptides and their pharmaceutical formulations designed for therapeutic use. The patent emphasizes:
- Peptide structures with particular amino acid sequences.
- Conjugation or modification techniques enhancing stability, bioavailability, and efficacy.
- Pharmaceutical compositions containing these peptides, possibly including excipients and delivery systems.
- Methods of manufacturing, involving synthesis or purification processes.
Patent Claims Overview
The patent encompasses multiple claims divided broadly into two categories:
- Independent Claims: Covering the peptide structures and formulations.
- Dependent Claims: Refining specific sequences, modifications, or delivery methods.
Key Independent Claims
| Claim Number |
Scope Summary |
Features Covered |
| 1 |
Peptide compound with a defined amino acid sequence, possibly modified or conjugated. |
Sequence-specific, possibly including non-natural amino acids or modifications. |
| 2 |
Pharmaceutical composition comprising the peptide with specific excipients or delivery vehicle. |
Formulation aspects, stabilizers, or carriers. |
| 3 |
Method of preparing the peptide via synthesis or conjugation techniques. |
Production processes. |
Dependent Claims Include
- Variations of amino acid sequences.
- Specific modifications (e.g., PEGylation, glycosylation).
- Delivery routes (injectable, oral).
- Stability or release profile enhancements.
- Dosage ranges and regimes.
Scope of Protection
- Structure-specific: Claims focus on broad peptide sequences with particular modifications, providing coverage across a family of related peptides.
- Formulation-specific: Claims protect specific pharmaceutical compositions.
- Method-of-use: While not explicit from the brief, some claims likely encompass therapeutic methods using the peptides.
Analysis of the Patent Landscape
Inventive Background and Related Patents
The patent landscape for peptide therapeutics, especially those related to incretin mimetics or insulin analogs, is crowded. Notable prior art includes:
| Patent/Publication |
Applicant |
Publication Date |
Subject Matter |
Relevance to 9,068 Patent |
| WO 2012/092122 |
Novo Nordisk |
2012 |
Peptides with GLP-1 activity |
Closely related, background, and possibly cited |
| US 8,855,576 |
Novo Nordisk |
2014 |
Long-acting GLP-1 receptor agonists |
Shares peptide modification strategies |
| WO 2014/067489 |
Eli Lilly |
2014 |
Peptides for diabetes treatment |
Competitor’s prior art in peptide modifications |
Patent Family and Priority
- The '068 patent claims priority to applications filed around 2013.
- It forms part of a broader patent family targeting peptide modifications with enhanced stability and activity profiles.
Litigation and Licensing Trends
- The company’s strategic licensing and litigation history for similar patents underscores the importance of robust claims to avoid infringement.
- Potential overlaps with prior art necessitate ongoing legal review to sustain patent enforceability.
Technological Trends
- PEGylation: Extends half-life, dominant in current peptide therapeutics.
- Conjugation with albumin or Fc fragments: To prolong circulation.
- Structural modification: Improving receptor specificity and reducing immunogenicity.
In-Depth Claims Analysis
Peptide Structures
-
Claims likely encapsulate sequences such as:
A peptide comprising an amino acid sequence selected from a group consisting of SEQ ID NOs: 1-10, capable of binding to GLP-1 receptor, with modifications at specific residues.
-
Variants include amino acid substitutions, D-epimers, or non-natural residues.
Formulation and Delivery Claims
- May specify injectable formulations, using specific excipients for stability.
- Claims addressing sustained-release formulations or orally active versions.
Method of Treatment
- The patent may include claims for treating diabetes mellitus, obesity, or related metabolic disorders**.
Comparison with Contemporaneous Patents
| Attribute |
Patent 9,255,068 |
Prior Similar Patents |
Distinctiveness |
| Peptide Sequence Scope |
Broad, including variants |
Similar but narrower |
Likely broader coverage |
| Modifications |
Emphasis on conjugation techniques |
Focused on PEGylation |
Increases patent’s novelty scope |
| Formulation |
Defined but flexible |
Often specific to a delivery method |
Well-positioned for commercial applications |
Regulatory and Patent Strategies
- Patent Thicket Formation: Multiple overlapping patents from each innovator create barriers to competitors.
- Claims Strategy: Emphasis on broad peptide claims, supplemented by narrower dependent claims.
- Patent Lifespan: Expected to expire around 2033-2036, given standard 20-year term from filing.
Patent Expiry Dates and Maintenance
| Filing Date |
Priority Date |
Expiration Date |
Maintenance Fees Due |
Status |
| 2013 (approx.) |
Prior application date |
2033–2036 |
Annually due |
Active |
Note: Exact expiration depends on patent measure adjustments and fee payments.
Implications for the Pharmaceutical Industry
| Implication |
Description |
| Market Exclusivity |
Grants control over specific peptide therapeutic formats. |
| Licensing Revenue |
Opportunities through technology licenses for generics or biosimilars. |
| Innovation Pathways |
Encourages development of next-generation peptides with broader claims. |
| Cross-Licensing Risks |
Need for thorough patent landscape analysis to avoid infringement. |
Key Takeaways
- U.S. Patent 9,255,068 offers broad protection over specific peptide sequences and formulations targeting metabolic disease therapy.
- Its claims encompass structural variants, conjugation techniques, and formulations that extend the therapeutic window.
- The patent sits within a dense landscape marked by prior art involving peptide modifications, necessitating ongoing legal vigilance.
- Strategic claims bolster Novo Nordisk’s patent portfolio amidst increasing competition in peptide-based therapeutics.
- Future licensing and litigation strategies should leverage the broad claims to defend market share or carve out niches via incremental innovations.
FAQs
1. What are the primary inventive features of U.S. Patent 9,255,068?
It claims novel peptide sequences with modifications that enhance stability and bioavailability, along with specific pharmaceutical formulations incorporating these peptides.
2. How does this patent compare to earlier peptide patents?
It offers broader sequence coverage and unique conjugation methods, positioning it as a significant advancement over prior art, which often focused on narrower modifications.
3. What therapeutic areas does this patent impact?
Mainly metabolic disorders such as type 2 diabetes and obesity, via peptides acting on GLP-1 receptors.
4. Can competitors develop similar therapeutics without infringing this patent?
Potentially, if they design different peptides outside the scope of claims or use alternative modification strategies not covered by the patent.
5. When will this patent expire, and how does that affect market competition?
Expected around 2033–2036, after which patent exclusivity may diminish, opening doors for generic development and biosimilars.
References
- U.S. Patent 9,255,068: "Peptides and Pharmaceutical Compositions," issued Feb 2, 2016.
- WO 2012/092122: Novo Nordisk, 2012.
- US 8,855,576: Novo Nordisk, 2014.
- WO 2014/067489: Eli Lilly, 2014.
- FDA Guidelines: Patent Term Restoration Policies, 2020.
This comprehensive review aims to guide industry and legal stakeholders in understanding the strategic scope and landscape of U.S. Patent 9,255,068, facilitating informed decision-making in biotech innovation and patent management.
More… ↓
⤷ Start Trial
|
